Martine A. Rothblatt Sells 8,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock
Martine A. Rothblatt Sells 8,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock
United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the firm's stock in a transaction that occurred on Thursday, January 19th. The shares were sold at an average price of $259.60, for a total value of $2,076,800.00. Following the sale, the chief executive officer now owns 130 shares of the company's stock, valued at approximately $33,748. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
联合治疗公司(纳斯达克：UTHR-GET评级)首席执行官马丁·A·罗斯布拉特在1月19日星期四的一笔交易中出售了8,000股该公司股票。这些股票的平均价格为259.60美元，总价值为2,076,800.00美元。出售后，首席执行官现在拥有130股公司股票，价值约33,748美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可以通过这个环节.
United Therapeutics Stock Up 0.6 %
联合治疗公司股票上涨0.6%
Shares of United Therapeutics stock opened at $261.70 on Friday. The business's fifty day moving average price is $270.84 and its two-hundred day moving average price is $241.25. The company has a debt-to-equity ratio of 0.18, a current ratio of 9.68 and a quick ratio of 9.39. The company has a market capitalization of $11.93 billion, a P/E ratio of 17.80, a PEG ratio of 1.54 and a beta of 0.62. United Therapeutics Co. has a 1-year low of $158.38 and a 1-year high of $283.09.
联合治疗公司的股票周五开盘报261.70美元。该业务的50日移动均线价格为270.84美元，200日移动均线价格为241.25美元。该公司的债务权益比为0.18，流动比率为9.68，速动比率为9.39。该公司市值为119.3亿美元，市盈率为17.80倍，聚乙二醇率为1.54倍，贝塔系数为0.62。联合治疗公司股价跌至158.38美元的一年低点和283.09美元的一年高点。
United Therapeutics (NASDAQ:UTHR – Get Rating) last announced its earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share for the quarter, beating the consensus estimate of $3.57 by $1.34. The firm had revenue of $516.00 million for the quarter, compared to the consensus estimate of $492.92 million. United Therapeutics had a return on equity of 16.63% and a net margin of 38.03%. As a group, research analysts forecast that United Therapeutics Co. will post 16.63 EPS for the current year.
联合治疗公司(纳斯达克：UTHR-GET评级)最近一次公布收益结果是在11月2日星期三。这家生物技术公司公布本季度每股收益为4.91美元，比普遍预期的3.57美元高出1.34美元。该公司本季度营收为5.16亿美元，而市场普遍预期为4.9292亿美元。联合治疗公司的股本回报率为16.63%，净利润率为38.03%。作为一个整体，研究分析师预测，联合治疗公司本年度的每股收益将达到16.63美元。
Institutional Trading of United Therapeutics
联合治疗公司的制度性交易
Analyst Ratings Changes
分析师评级发生变化
Several brokerages have recently commented on UTHR. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, November 3rd. Wedbush lifted their target price on United Therapeutics from $250.00 to $305.00 in a research report on Thursday, November 3rd. HC Wainwright lifted their target price on United Therapeutics from $255.00 to $300.00 and gave the stock a "buy" rating in a research report on Thursday, November 3rd. Oppenheimer lifted their target price on United Therapeutics from $325.00 to $375.00 and gave the stock an "outperform" rating in a research report on Thursday, November 3rd. Finally, JPMorgan Chase & Co. lifted their target price on United Therapeutics from $240.00 to $265.00 and gave the stock an "overweight" rating in a research report on Thursday, November 3rd. Two analysts have rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $283.64.
几家券商最近对UTHR发表了评论。在11月3日星期四的一份研究报告中，StockNews.com将联合治疗公司的评级从“买入”上调至“强力买入”。韦德布什在11月3日星期四的一份研究报告中将他们对联合治疗公司的目标价从250.00美元上调至305.00美元。11月3日周四，在一份研究报告中，HC Wainwright将联合治疗公司的目标价从255.00美元上调至300.00美元，并给予该股“买入”评级。奥本海默将联合治疗公司的目标价从325.00美元上调至375.00美元，并在11月3日周四的一份研究报告中给出了该股的“跑赢大盘”评级。最终，摩根大通将联合治疗公司的目标价从240.00美元上调至265.00美元，并在11月3日周四的一份研究报告中给予该股“增持”评级。两名分析师对该股的评级为卖出，一名分析师给予持有评级，九名分析师给予买入评级，一名分析师对该股给予强烈买入评级。根据MarketBeat的数据，该公司的平均评级为“适度买入”，共识目标价为283.64美元。
About United Therapeutics
关于联合治疗公司
(Get Rating)
(获取评级)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
联合治疗公司是一家生物技术公司，致力于产品的开发和商业化，以满足美国和国际上慢性和危及生命的疾病患者未得到满足的医疗需求。其商业疗法包括用于治疗肺动脉高压(PAH)患者的Remodlin，以减轻运动相关症状；TYVASO，一种前列环素类似物Treprostinil的吸入制剂，用于增强PAH患者的运动能力；Treprostinil的片剂Orenitram，用于增强PAH患者的运动能力；Unitusin，用于治疗高危神经母细胞瘤；以及AdCirca，口服PDE-5抑制剂，用于增强PAH患者的运动能力。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 免费获取StockNews.com关于联合治疗(UTHR)的研究报告
- 市场回顾周-1/16-1/20
- Old Dominion是否表明Trucking正在踩刹车？
- 诺德斯特龙对零售业降价的担忧
- 埃克森美孚股票：在Buy Point附近
- 高股息率的必和必拓认为中国推动了23年的增长
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受联合治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对联合治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。